

**Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance**

Yuna Sugimoto<sup>1\*</sup>; Kayo Yamamura<sup>1</sup>; Tomoyo Takayama<sup>1</sup>; Yasuhiko Fukuta<sup>1</sup>; Kazuo Aoki<sup>2</sup>, Katsunaka Mikami<sup>3</sup>; Akemi Tomoda<sup>4</sup>

*\*Correspondence: Sugimoto.Yuna@otsuka.jp*

<sup>1</sup>Pharmacovigilance Department, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan

<sup>2</sup>Medical Affairs Department, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.

<sup>3</sup>Department of Psychiatry, Tokai University School of Medicine, Kanagawa, Japan.

<sup>4</sup>Research Center for Child Mental Development, University of Fukui, Fukui, Japan.

**Additional file 1.** Treatment continuation rate (Kaplan-Meier plot)

